Endovascular thrombectomy (EVT) does not lead to better outcomes at 90 days compared with usual care or best medical ...

Roche’s Gazyva/Gazyvaro (obinutuzumab) has demonstrated superiority over standard therapy in patients with active lupus ...

Sepsis, a life-threatening organ dysfunction, is responsible for an estimated 1 in 5 deaths globally and 1 in 3 deaths that ...

Gazyva/Gazyvaro (obinutuzumab) was found to significantly improve complete renal response in lupus nephritis patients, ...

Anthos is currently conducting a phase 3 clinical study in patients with atrial fibrillation with high risk for stroke or systemic embolism (LILAC-TIMI 76) as well as two phase 3 studies in patients ...

We recently published a list of 10 Best Annual Dividend Stocks To Buy Now. In this article, we are going to take a look at where Roche Holding AG (OTC:RHHBY) stands against other best annual dividend ...

The team has issued an urgent plea. Experts issue urgent call to action for new government policy targeting children's health ...

Topline data from FIBRONEER™-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change ...

About Abelacimab Abelacimab is a novel, investigational, highly selective, fully human monoclonal antibody that binds tightly to Factor XI to block its activation and prevent the generation of the ...

Topline data from FIBRONEER-ILD show that the investigational compound nerandomilast met its primary endpoint, which was the absolute change from baseline in forced vital capacity [mL] at week 52 vers ...